Tango Therapeutics (NASDAQ:TNGX) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Tango Therapeutics (NASDAQ:TNGX) from a buy rating to a hold rating in a research note released on Saturday.

TNGX has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Wolfe Research started coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Wedbush increased their price objective on shares of Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tango Therapeutics in a report on Thursday. Finally, HC Wainwright boosted their target price on shares of Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tango Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Tango Therapeutics Trading Up 0.7%

NASDAQ TNGX opened at $16.95 on Friday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -19.48 and a beta of 1.76. The stock has a 50-day moving average of $11.86 and a 200 day moving average of $9.46. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $17.63.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 66.01% and a negative net margin of 151.15%. Equities analysts predict that Tango Therapeutics will post -1.19 EPS for the current fiscal year.

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of Tango Therapeutics stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the sale, the insider owned 132,873 shares of the company’s stock, valued at $1,696,788.21. The trade was a 29.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $374,162.94. Following the sale, the director directly owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. The trade was a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 113,633 shares of company stock worth $1,420,857. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TNGX. Global Retirement Partners LLC purchased a new stake in Tango Therapeutics during the 4th quarter valued at about $35,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in Tango Therapeutics in the 4th quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Tango Therapeutics by 52.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS?0015/vopimetostat in MTAP?deleted, RAS?mutant cancers expands Tango’s clinical footprint and creates near?term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy?side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share?price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell?side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.